PROFILPELAJAR.COM

Deksmedetomidin
(IUPAC) ime
	(S)-4-[1-(2,3-dimetilfenil)etil]-3H-imidazol
Klinički podaci
Robne marke	Precedex, Dexdor
AHFS/Drugs.com	Monografija
Identifikatori
CAS broj	113775-47-6
ATC kod	N05CM18
PubChem	68602
DrugBank	DB00633
ChemSpider	4470605
UNII	67VB76HONO
KEGG	D00514
ChEBI	CHEBI:4466
ChEMBL	CHEMBL778
Hemijski podaci
Formula	C13H16N2
Mol. masa	200,28 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C13H16N2/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13/h4-8,11H,1-3H3,(H,14,15)/t11-/m0/s1 ; Key: CUHVIMMYOGQXCV-NSHDSACASA-N
Farmakokinetički podaci
Vezivanje za proteine plazme	94%
Metabolizam	Skoro potpuni hepatički metabolizam do neaktivnog metabolita
Poluvreme eliminacije	2 sata
Izlučivanje	Urinarno
Farmakoinformacioni podaci
Trudnoća	C(US)
Pravni status	℞-only (SAD)
Način primene	Intravenozna infuzija

Deksmedetomidin (Precedeks, Deksdor) je sedativ koji koristi za intezivnu negu i anesteziju. On je relativno neobičan po tome što omogućava sedaciju bez izazivanja respiratorne depresije. Poput klonidina, on je agonist α₂-adrenergičkog receptora u mozgu.^[6] On je S-enantiomer medetomidina,^[7] koji se koristi u veterini.

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ Cormack JR, Orme RM, Costello TG (2005). „The role of alpha2-agonists in neurosurgery”. Journal of Clinical Neuroscience 12 (4): 375-8. DOI:10.1016/j.jocn.2004.06.008. PMID 15925765.
↑ PubChem 5311068

Literatura

„Dosing Guidelines for Precedex”. Arhivirano iz originala na datum 2011-07-15. Pristupljeno 21. 11. 2010.
Jackson KC, Wang Z, Wohlt P, Fine PG (2006). „Dexmedetomidine a novel analgesic with palliative medicine potential”. J Pain and Palliative Care Pharmacotherapy 20 (2): 23-7. DOI:10.1080/J354v20n02_05. PMID 16702133.
Menon DV, Wang Z, Fadel PJ, Arbique D, Leonard D, Li JL, Victor RG, Vongpatanasin W. (2007). „Central sympatholysis as a novel countermeasure for cocaine-induced sympathetic activation and vasoconstriction in humans”. J Am Coll Cardiol 50 (7): 626-33. DOI:10.1016/j.jacc.2007.03.060. PMID 17692748.
O'Connor, M; Bucknall, T; Manias, E (2009). „Sedation Management in Australian and New Zealand Intensive Care Units: Doctors' and Nurses' Practices and Opinions”. Am J Crit Care 19 (3): 285-95. DOI:10.4037/ajcc2009541. PMID 19770414.
Pandharipande, PP; Pun, BT; Herr, DL; Maze, M; Girard, TD; Miller, RR; Shintani, AK; Thompson, JL i dr.. (2007). „Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial”. JAMA 298 (22): 2644-53. DOI:10.1001/jama.298.22.2644. PMID 18073360.
Paris A, Tonner PH (2005). „Dexmedetomidine in anaesthesia”. Current Opinion in Anaesthesiology 18 (4): 412-8. DOI:10.1097/01.aco.0000174958.05383.d5. PMID 16534267.
Riker RR, Shehabi Y, Bokesch PM, Ceraso D, Wisemandle W, Koura F, Whitten P, Margolis BD, Byrne DW, Ely EW, Rocha MG (2009). „Dexmedetomidine vs Midazolam for Sedation of Critically Ill Patients: A Randomized Trial”. JAMA 301 (5): 489-99. DOI:10.1001/jama.2009.56. PMID 19188334.
Dasta JF, Kane-Gill SL, Pencina M, et al (2010). „A cost-minimization analysis of dexmedetomidine compared with midazolam for long-term sedation in the intensive care unit”. Crit Care Med 38 (2): 497-503. PMID 19789442.
Wunsch H. (2011). „Weighing the Costs and Benefits of a Sedative”. JAMA 307 (11): 1195-1197. DOI:10.1001/jama.2012.319.